Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients

O. Bartošová, C. Bonnet, O. Ulmanová, M. Šíma, F. Perlík, E. Růžička, O. Slanař,

. 2018 ; 125 (4) : 699-703. [pub] 20171219

Language English Country Austria

Document type Journal Article

Grant support
204022 UNCE - International
Q25 Progres - International

Dopamine was shown to induce mydriasis by excitation of alpha-adrenergic receptors at the dilator pupillae muscle. Pupilla diameter may thus serve as an indirect measure of peripheral pharmacokinetics of L-DOPA and dopamine. The aim of this study is to evaluate the effect of L-DOPA dosage on pupillometric parameters in Parkinson's disease (PD) patients. Sixteen PD patients and 14 healthy control subjects (CS) were studied. The statistical analysis revealed significant differences between CS and PD patients for the mean maximum and minimum pupil diameters (p = 0.017, p = 0.028, respectively), with higher values found in PD. Moreover, a significant dose-response relationship was found between the maximum pupil diameter and both the morning L-DOPA dose (R 2 = 0.78) and the total daily L-DOPA dose (R 2 = 0.93). A sigmoid-shaped curve best describes the dose-response relationship, with a ceiling effect at about 400 mg L-DOPA daily dose. In conclusion, measuring pupillometric parameters represents a sensitive tool for non-invasive evaluation of the peripheral effect of L-DOPA, especially with daily doses below 400 mg L-DOPA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045576
003      
CZ-PrNML
005      
20200115091006.0
007      
ta
008      
200109s2018 au f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00702-017-1829-1 $2 doi
035    __
$a (PubMed)29255941
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a au
100    1_
$a Bartošová, O $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. olga.matouskova@lf1.cuni.cz.
245    10
$a Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients / $c O. Bartošová, C. Bonnet, O. Ulmanová, M. Šíma, F. Perlík, E. Růžička, O. Slanař,
520    9_
$a Dopamine was shown to induce mydriasis by excitation of alpha-adrenergic receptors at the dilator pupillae muscle. Pupilla diameter may thus serve as an indirect measure of peripheral pharmacokinetics of L-DOPA and dopamine. The aim of this study is to evaluate the effect of L-DOPA dosage on pupillometric parameters in Parkinson's disease (PD) patients. Sixteen PD patients and 14 healthy control subjects (CS) were studied. The statistical analysis revealed significant differences between CS and PD patients for the mean maximum and minimum pupil diameters (p = 0.017, p = 0.028, respectively), with higher values found in PD. Moreover, a significant dose-response relationship was found between the maximum pupil diameter and both the morning L-DOPA dose (R 2 = 0.78) and the total daily L-DOPA dose (R 2 = 0.93). A sigmoid-shaped curve best describes the dose-response relationship, with a ceiling effect at about 400 mg L-DOPA daily dose. In conclusion, measuring pupillometric parameters represents a sensitive tool for non-invasive evaluation of the peripheral effect of L-DOPA, especially with daily doses below 400 mg L-DOPA.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antiparkinsonika $x aplikace a dávkování $7 D000978
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a levodopa $x aplikace a dávkování $7 D007980
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Parkinsonova nemoc $x farmakoterapie $7 D010300
650    _2
$a pupila $x účinky léků $7 D011680
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bonnet, C $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Ulmanová, O $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Šíma, M $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Perlík, F $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Růžička, E $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Slanař, O $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
773    0_
$w MED00010058 $t Journal of neural transmission (Vienna, Austria : 1996) $x 1435-1463 $g Roč. 125, č. 4 (2018), s. 699-703
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29255941 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200115091339 $b ABA008
999    __
$a ok $b bmc $g 1483844 $s 1084249
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 125 $c 4 $d 699-703 $e 20171219 $i 1435-1463 $m Journal of neural transmission $n J Neural Transm $x MED00010058
GRA    __
$a 204022 $p UNCE $2 International
GRA    __
$a Q25 $p Progres $2 International
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...